Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06325046 · ClinicalTrials.gov registry record · NA

Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer

A NA study of Stage III Prostate Cancer AJCC v8 and Stage II Prostate Cancer AJCC v8, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
144
Enrollment target
5
Study locations

NCT06325046 is a NA study of Stage III Prostate Cancer AJCC v8 and Stage II Prostate Cancer AJCC v8 that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 144 participants, below the 244-participant average among 28 other Stage III Prostate Cancer AJCC v8 trials with a reported enrollment target (41% lower). The trial reports 5 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06325046, a NA study of Stage III Prostate Cancer AJCC v8 and Stage II Prostate Cancer AJCC v8, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
144 participants
Enrollment target
5
Study locations

Study Summary

This clinical trial evaluates changes in quality of life after two treatments with near margin-less adaptive radiation therapy (ART) compared to five treatments with standard stereotactic ablative body radiotherapy (SABR) in patients with prostate cancer that has not spread to other parts of the body (localized). ART is a type of radiation therapy that uses information gathered during the treatment cycle to inform, guide, and alter future radiation treatments with respect to location and dose. It may be able to deliver radiation to the site of disease over a shorter time and with smaller margins (less treatment delivered to nearby healthy tissues). SABR is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Shorter duration near margin-less ART may be just as effective at treating patients with localized prostate cancer but have less quality of life side effects than standard SABR.

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • PROCEDURE Cone-Beam Computed Tomography
  • PROCEDURE Stereotactic Ablative Radiotherapy
  • RADIATION Image-Guided Adaptive Radiation Therapy

Study Locations (5)

Minnesota

  • Mayo Clinic Health System in Albert Lea - Albert Lea
  • Mayo Clinic Health System-Mankato - Mankato
  • Mayo Clinic in Rochester - Rochester

Wisconsin

  • Mayo Clinic Health System-Eau Claire - Eau Claire
  • Mayo Clinic Health System-Franciscan Healthcare - La Crosse

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2024-08-15
Est. Completion 2026-08
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT06325046

The ClinicalTrials.gov registry entry for NCT06325046 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 244-participant average among 28 other Stage III Prostate Cancer AJCC v8 trials with a reported enrollment target (41% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Stage III Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.

NCT06325046 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT06325046 about?

NCT06325046 is a clinical study titled "Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer". This clinical trial evaluates changes in quality of life after two treatments with near margin-less adaptive radiation therapy (ART) compared to five treatments with standard stereotactic ablative body radiotherapy (SABR) in patients with prostate cancer that has not spread to other parts of the bod...

What is the current status of trial NCT06325046?

This trial is currently recruiting. It is a NA study. The enrollment target is 144 participants. The study started on 2024-08-15. Estimated completion is 2026-08.

What conditions does trial NCT06325046 study?

This clinical trial studies the following conditions: Stage III Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage I Prostate Cancer AJCC v8, Localized Prostate Adenocarcinoma.

What interventions are being tested in trial NCT06325046?

The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Cone-Beam Computed Tomography (PROCEDURE), Stereotactic Ablative Radiotherapy (PROCEDURE), Image-Guided Adaptive Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT06325046?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06325046 being conducted?

This trial has 5 study locations across Minnesota, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stage III Prostate Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.